Free Trial
NYSE:AVNS

Avanos Medical Q1 2026 Earnings Report

Avanos Medical logo
$24.98 +0.01 (+0.02%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Avanos Medical EPS Results

Actual EPS
$0.22
Consensus EPS
$0.16
Beat/Miss
Beat by +$0.06
One Year Ago EPS
$0.26

Avanos Medical Revenue Results

Actual Revenue
$182.20 million
Expected Revenue
$170.00 million
Beat/Miss
Beat by +$12.20 million
YoY Revenue Growth
+8.80%

Avanos Medical Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 5, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Avanos Medical's Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Avanos Medical Earnings Headlines

Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
Summers Value Partners Q1 2026 Partner Letter
See More Avanos Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avanos Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avanos Medical and other key companies, straight to your email.

About Avanos Medical

Avanos Medical (NYSE:AVNS) is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms. These solutions are intended to help reduce reliance on systemic opioids and support accelerated recovery protocols. The enteral feeding business provides a range of feeding tubes, pumps and accessories to deliver nutrition directly to the gastrointestinal tract, serving patients with swallowing disorders or nutritional deficiencies. In respiratory care, the company’s offerings include patient interfaces, breathing circuits and related disposables that aid in noninvasive ventilation, oxygen therapy and airway management.

Avanos Medical was established as a standalone company in January 2017 following a spin-off from Kimberly-Clark’s healthcare business. Headquartered in Alpharetta, Georgia, the company maintains a presence in key markets across North America, Europe, Asia Pacific and Latin America. Its global sales and distribution network supports hospitals, surgical centers and home healthcare providers with both direct sales teams and distributor partnerships.

Under the leadership of President and Chief Executive Officer Mike Coolbaugh, Avanos pursues a strategy centered on innovation, operational excellence and targeted acquisitions to expand its product portfolio and geographic reach. The company continues to invest in research and development to advance its current offerings and explore new technologies that address evolving clinical needs in pain management, nutritional support and respiratory therapy.

View Avanos Medical Profile